IL161834A0 - Pharmaceutical compositions and methods for administering ep2 receptor selective agonists - Google Patents
Pharmaceutical compositions and methods for administering ep2 receptor selective agonistsInfo
- Publication number
- IL161834A0 IL161834A0 IL16183402A IL16183402A IL161834A0 IL 161834 A0 IL161834 A0 IL 161834A0 IL 16183402 A IL16183402 A IL 16183402A IL 16183402 A IL16183402 A IL 16183402A IL 161834 A0 IL161834 A0 IL 161834A0
- Authority
- IL
- Israel
- Prior art keywords
- administering
- methods
- pharmaceutical compositions
- selective agonists
- receptor selective
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/18—Sulfonamides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4406—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
- A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Physical Education & Sports Medicine (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US33515601P | 2001-11-30 | 2001-11-30 | |
| PCT/IB2002/004368 WO2003045371A1 (en) | 2001-11-30 | 2002-10-21 | Pharmaceutical compositions and methods for administering ep2 receptor selective agonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL161834A0 true IL161834A0 (en) | 2005-11-20 |
Family
ID=23310510
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL16183402A IL161834A0 (en) | 2001-11-30 | 2002-10-21 | Pharmaceutical compositions and methods for administering ep2 receptor selective agonists |
Country Status (24)
| Country | Link |
|---|---|
| US (1) | US20030166631A1 (es) |
| EP (1) | EP1448182A1 (es) |
| JP (1) | JP2005513030A (es) |
| KR (1) | KR20040063981A (es) |
| CN (1) | CN1599605A (es) |
| AR (1) | AR037593A1 (es) |
| AU (1) | AU2002348948A1 (es) |
| BR (1) | BR0214614A (es) |
| CA (1) | CA2468494A1 (es) |
| GT (1) | GT200200235A (es) |
| HN (1) | HN2002000336A (es) |
| IL (1) | IL161834A0 (es) |
| MX (1) | MXPA04003689A (es) |
| NO (1) | NO20042272L (es) |
| NZ (1) | NZ532209A (es) |
| PA (1) | PA8559601A1 (es) |
| PE (1) | PE20030660A1 (es) |
| PL (1) | PL370914A1 (es) |
| RU (1) | RU2004116318A (es) |
| SV (1) | SV2004001417A (es) |
| TW (1) | TW200300342A (es) |
| UY (1) | UY27556A1 (es) |
| WO (1) | WO2003045371A1 (es) |
| ZA (1) | ZA200402795B (es) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA67754C2 (uk) * | 1997-10-10 | 2004-07-15 | Пфайзер, Інк. | Агоністи простагландину, фармацевтична композиція на їх основі (варіанти), спосіб нарощення та збереження кісткової маси у хребетних та спосіб лікування (варіанти) |
| EP2422814A1 (en) * | 2003-07-25 | 2012-02-29 | Ono Pharmaceutical Co., Ltd. | Remedy for cartilage-related diseases |
| US7326732B2 (en) | 2004-02-12 | 2008-02-05 | Pharmagene Laboratories Limited | EP2 receptor agonists |
| AU2005261740A1 (en) | 2004-07-08 | 2006-01-19 | Novo Nordisk A/S | Polypeptide protracting tags comprising a tetrazole moiety |
| WO2007017687A2 (en) | 2005-08-09 | 2007-02-15 | Asterand Uk Limited | Ep2 receptor agonists |
| US7915316B2 (en) * | 2005-08-22 | 2011-03-29 | Allergan, Inc | Sulfonamides |
| AU2007223981B2 (en) * | 2006-03-07 | 2011-12-01 | Osteoscreen Ip, Llc | HMG Co-A reductase inhibitor enhancement of bone and cartilage |
| CA2659184C (en) * | 2006-07-28 | 2012-02-21 | Pfizer Products Inc. | Ep2 agonists |
| JP5271272B2 (ja) * | 2006-11-16 | 2013-08-21 | ジェンムス ファーマ インコーポレイティド | Ａ型インフルエンザウィルス感染の治療のための薬剤としてのｅｐ２およびｅｐ４作動薬 |
| CZ2010180A3 (cs) * | 2007-08-21 | 2010-10-13 | Senomyx, Inc | Identifikace lidských T2R receptoru, které reagují na horké slouceniny, které vyvolavají horkou chut v kompozicích, a jejich použití v testech pro identifikaci sloucenin, které inhibují (blokují) horkou chut v kompozicích a jejich použití |
| EP2149554A1 (de) | 2008-07-30 | 2010-02-03 | Bayer Schering Pharma Aktiengesellschaft | Indolylamide als Modulatoren des EP2-Rezeptors |
| EP2149552A1 (de) | 2008-07-30 | 2010-02-03 | Bayer Schering Pharma AG | 5,6 substituierte Benzamid-Derivate als Modulatoren des EP2-Rezeptors |
| EP2149551A1 (de) | 2008-07-30 | 2010-02-03 | Bayer Schering Pharma AG | N-(Indol-3-ylalkyl)-(hetero)arylamidderivate als Modulatoren des EP2-Rezeptors |
| WO2010116270A1 (en) | 2009-04-10 | 2010-10-14 | Pfizer Inc. | Ep2/4 agonists |
| FR3034678A1 (fr) * | 2015-04-07 | 2016-10-14 | Geocorail | Dispositif, procede et compose pour la reconstruction osseuse d'un vertebre. |
| WO2017139561A1 (en) | 2016-02-12 | 2017-08-17 | Bluebird Bio, Inc. | Vcn enhancer compositions and methods of using the same |
| RU2744603C2 (ru) * | 2016-02-12 | 2021-03-11 | Блубёрд Био, Инк. | Композиции, повышающие число копий вектора (чкв), и способы их применения |
| US12042503B2 (en) | 2020-02-12 | 2024-07-23 | Cytoagents, Inc. | Compositions and methods for treating coronavirus infections |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) * | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| US4789663A (en) * | 1984-07-06 | 1988-12-06 | Collagen Corporation | Methods of bone repair using collagen |
| DE69738613T2 (de) * | 1996-12-20 | 2009-04-30 | Pfizer Inc. | Prävention und behandlung von skeletterkrankungen mit ep2 subtyp selektiven prostaglandin e2 agonisten |
| UA59384C2 (uk) * | 1996-12-20 | 2003-09-15 | Пфайзер, Інк. | Похідні сульфонамідів та амідів як агоністи простагландину, фармацевтична композиція та способи лікування на їх основі |
| US6071982A (en) * | 1997-04-18 | 2000-06-06 | Cambridge Scientific, Inc. | Bioerodible polymeric semi-interpenetrating network alloys for surgical plates and bone cements, and method for making same |
| UA67754C2 (uk) * | 1997-10-10 | 2004-07-15 | Пфайзер, Інк. | Агоністи простагландину, фармацевтична композиція на їх основі (варіанти), спосіб нарощення та збереження кісткової маси у хребетних та спосіб лікування (варіанти) |
| US20010056060A1 (en) * | 2000-02-07 | 2001-12-27 | Cameron Kimberly O. | Treatment of osteoporsis with EP2/EP4 receptor selective agonists |
-
2002
- 2002-10-21 BR BR0214614-2A patent/BR0214614A/pt not_active IP Right Cessation
- 2002-10-21 CA CA002468494A patent/CA2468494A1/en not_active Abandoned
- 2002-10-21 WO PCT/IB2002/004368 patent/WO2003045371A1/en active Application Filing
- 2002-10-21 PL PL02370914A patent/PL370914A1/xx not_active Application Discontinuation
- 2002-10-21 RU RU2004116318/14A patent/RU2004116318A/ru not_active Application Discontinuation
- 2002-10-21 MX MXPA04003689A patent/MXPA04003689A/es not_active Application Discontinuation
- 2002-10-21 IL IL16183402A patent/IL161834A0/xx unknown
- 2002-10-21 JP JP2003546873A patent/JP2005513030A/ja not_active Abandoned
- 2002-10-21 KR KR10-2004-7008309A patent/KR20040063981A/ko not_active Application Discontinuation
- 2002-10-21 AU AU2002348948A patent/AU2002348948A1/en not_active Abandoned
- 2002-10-21 CN CNA028239385A patent/CN1599605A/zh active Pending
- 2002-10-21 NZ NZ532209A patent/NZ532209A/en unknown
- 2002-10-21 EP EP02781458A patent/EP1448182A1/en not_active Withdrawn
- 2002-11-21 GT GT200200235A patent/GT200200235A/es unknown
- 2002-11-25 TW TW091134181A patent/TW200300342A/zh unknown
- 2002-11-26 PE PE2002001133A patent/PE20030660A1/es not_active Application Discontinuation
- 2002-11-26 US US10/305,649 patent/US20030166631A1/en not_active Abandoned
- 2002-11-27 HN HN2002000336A patent/HN2002000336A/es unknown
- 2002-11-28 UY UY27556A patent/UY27556A1/es not_active Application Discontinuation
- 2002-11-28 AR ARP020104592A patent/AR037593A1/es unknown
- 2002-11-29 SV SV2002001417A patent/SV2004001417A/es not_active Application Discontinuation
- 2002-11-29 PA PA20028559601A patent/PA8559601A1/es unknown
-
2004
- 2004-04-13 ZA ZA200402795A patent/ZA200402795B/en unknown
- 2004-06-01 NO NO20042272A patent/NO20042272L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| BR0214614A (pt) | 2004-09-14 |
| PA8559601A1 (es) | 2003-07-28 |
| WO2003045371A1 (en) | 2003-06-05 |
| MXPA04003689A (es) | 2004-07-23 |
| EP1448182A1 (en) | 2004-08-25 |
| GT200200235A (es) | 2003-06-25 |
| SV2004001417A (es) | 2004-02-24 |
| CN1599605A (zh) | 2005-03-23 |
| PL370914A1 (en) | 2005-06-13 |
| CA2468494A1 (en) | 2003-06-05 |
| US20030166631A1 (en) | 2003-09-04 |
| KR20040063981A (ko) | 2004-07-15 |
| PE20030660A1 (es) | 2003-08-04 |
| NZ532209A (en) | 2007-05-31 |
| UY27556A1 (es) | 2003-06-30 |
| AU2002348948A1 (en) | 2003-06-10 |
| RU2004116318A (ru) | 2005-03-27 |
| HN2002000336A (es) | 2003-02-10 |
| ZA200402795B (en) | 2005-04-13 |
| NO20042272L (no) | 2004-07-28 |
| TW200300342A (en) | 2003-06-01 |
| AR037593A1 (es) | 2004-11-17 |
| JP2005513030A (ja) | 2005-05-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL161834A0 (en) | Pharmaceutical compositions and methods for administering ep2 receptor selective agonists | |
| HUP0203453A3 (en) | Quinazoline derivatives as vegf inhibitors, process for their preparation, pharmaceutical compositions containing them and their use | |
| HUP0203638A3 (en) | Betha2-adrenergic receptor agonists and pharmaceutical compositions containing them and their use | |
| IL159725A0 (en) | Pharmaceutical compositions containing benzimidazole derivatives | |
| HUP0203122A3 (en) | Fab i inhibitors, process for their preparation, pharmaceutical compositions containing them and their use | |
| HUP0303849A3 (en) | Benzimidazole and pyridylimidazole derivatives as ligands for gaba receptors and pharmaceutical compositions containing them | |
| HUP0303258A3 (en) | N-substituted nonaryl-heterocyclic nmda/nr2b antagonists and pharmaceutical compositions containing them | |
| HUP0300894A3 (en) | Substituted beta-carbolines, process for their preparation, pharmaceutical compositions containing them and their use | |
| EP1551402A4 (en) | PHARMACEUTICAL COMPOSITIONS NOT INDUCING ABUSE | |
| HUP0303530A3 (en) | Stituted pyrroloquinolines and pyridoquinolines as serotonin agonists and antagonists and pharmaceutical compositions containing them | |
| HK1059575A1 (en) | Nmda receptor agonist pharmaceutical compositions | |
| IL162185A0 (en) | Phenylpropionate derivatives, methods for the preparation thereof and pharmaceutical compositions containing the same | |
| HK1081964A1 (en) | Imidazopyridine derivatives, preparation method and pharmaceutical compositions containing same | |
| EG24194A (en) | 5ht-a-partial agonist pharmaceutical compositions | |
| HUP0302770A3 (en) | Tripeptidyl peptidase inhibitors, process for their preparation and pharmaceutical compositions containing them | |
| HUP0400317A3 (en) | Beta-carboline derivatives, process for their preparation, their use and pharmaceutical compositions containing them | |
| HUP0203976A3 (en) | Adenozine a3 receptors, process for their preparation and pharmaceutical compositions containing them | |
| IL163643A0 (en) | Oxazolidinone derivatives, processes for their forpreparation, and pharmaceutical compositions containing them | |
| EP1501352A4 (en) | METHOD AND COMPOSITIONS FOR PROTRACTED ACTIVE SUBSTANCE | |
| AU2003284885A8 (en) | Device and methods for sequential, regional delivery of multiple cytotoxic agents | |
| IL153487A0 (en) | Pharmaceutical compositions and methods for use | |
| HUP0500958A3 (en) | 2-arylimino-2,3-dihydrothiazole derivatives, methods for preparing them, therapeutic use thereof and pharmaceutical compositions containing them | |
| IL153897A0 (en) | Pharmaceutical compositions and methods for use | |
| IL154986A0 (en) | Triazolo-epothilone derivatives, pharmaceutical compositions containing the same and methods for the preparation thereof | |
| AU2003224808A8 (en) | Compositions and methods for delivering pharmaceutically active agents using nanoparticulates |